Antibodies to human IL-10 neutralize ebvIL-10-mediated cytokine suppression but have no effect on cmvIL-10 activity

Virus Research

Volumn 153, Issue 2, 2010, Pages 265-268

  Brodeur, Noelle D ^a   Spencer, Juliet V ^a  

^a UNIVERSITY OF SAN FRANCISCO   (United States)

Author keywords

Antibodies; Cytokines; Cytomegalovirus; Immune suppression

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CROSS REACTION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN CYTOMEGALOVIRUS; MONOCYTE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTIBODIES; ANTIBODIES, NEUTRALIZING; CROSS REACTIONS; CYTOMEGALOVIRUS; HERPESVIRUS 4, HUMAN; HUMANS; INTERLEUKIN-10; NEUTRALIZATION TESTS; VIRAL PROTEINS;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 5;

EID: 77957289287     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.08.012     Document Type: Article

References (30)

1. Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy-review of a new approach. Pharmacol. Rev. 2003, 55(2):241-269.
2. Blackburn S.D., Wherry E.J. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 2007, 15(4):143-146.
3. Blay J.Y., Burdin N., Rousset F., Lenoir G., Biron P., Philip T., Banchereau J., Favrot M.C. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993, 82(7):2169-2174.
4. Brooks D.G., Lee A.M., Elsaesser H., McGavern D.B., Oldstone M.B. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J. Exp. Med. 2008, 205(3):533-541.
5. Brooks D.G., Trifilo M.J., Edelmann K.H., Teyton L., McGavern D.B., Oldstone M.B. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 2006, 12(11):1301-1309.
6. Budiani D.R., Hutahaean S., Haryana S.M., Soesatyo M.H., Sosroseno W. Interleukin-10 levels in Epstein-Barr virus-associated nasopharyngeal carcinoma. J. Microbiol. Immunol. Infect. 2002, 35(4):265-268.
7. Clerici M., Balotta C., Salvaggio A., Riva C., Trabattoni D., Papagno L., Berlusconi A., Rusconi S., Villa M.L., Moroni M., Galli M. Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood 1996, 88(2):574-579.
8. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J.E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 1991, 174(4):915-924.
9. Ejrnaes M., von Herrath M.G. Cure of chronic viral infection by neutralizing antibody treatment. Autoimmun. Rev. 2007, 6(5):267-271.
10. Fiorentino D.F., Bond M.W., Mosmann T.R. Two types of mouse T helper cell. J. Exp. Med. 1989, 170(6):2081-2095.
11. Hsu D.H., de Waal Malefyt R., Fiorentino D.F., Dang M.N., Vieira P., de Vries J., Spits H., Mosmann T.R., Moore K.W. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 1990, 250(4982):830-832.
12. Humphreys I.R., de Trez C., Kinkade A., Benedict C.A., Croft M., Ware C.F. Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J. Exp. Med. 2007, 204(5):1217-1225.
13. Jenkins C., Abendroth A., Slobedman B. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J. Virol. 2004, 78(3):1440-1447.
14. Jenkins C., Garcia W., Godwin M.J., Spencer J.V., Stern J.L., Abendroth A., Slobedman B. Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection. J. Virol. 2008, 82(7):3736-3750.
15. Jones B.C., Logsdon N.J., Josephson K., Cook J., Barry P.A., Walter M.R. Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc. Natl. Acad. Sci. U.S.A. 2002, 99(14):9404-9409.
16. Kane M., Golovkina T. Common threads in persistent viral infections. J. Virol. 2010, 84(9):4116-4123.
17. Kotenko S.V., Saccani S., Izotova L.S., Mirochnitchenko O.V., Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc. Natl. Acad. Sci. U.S.A. 2000, 97(4):1695-1700.
18. Liu Y., de Waal Malefyt R., Briere F., Parham C., Bridon J.M., Banchereau J., Moore K.W., Xu J. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J. Immunol. 1997, 158(2):604-613.
19. Lockridge K.M., Zhou S.S., Kravitz R.H., Johnson J.L., Sawai E.T., Blewett E.L., Barry P.A. Primate cytomegaloviruses encode and express an IL-10-like protein. Virology 2000, 268(2):272-280.
20. Martinic M.M., von Herrath M.G. Novel strategies to eliminate persistent viral infections. Trends Immunol. 2008, 29(3):116-124.
21. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
22. Mosser D.M., Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 2008, 226:205-218.
23. Nordoy I., Muller F., Nordal K.P., Rollag H., Lien E., Aukrust P., Froland S.S. The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J. Infect. Dis. 2000, 181(1):51-57.
24. Ordemann J., Jacobi C.A., Braumann C., Schwenk W., Volk H.D., Muller J.M. Immunomodulatory changes in patients with colorectal cancer. Int. J. Colorectal Dis. 2002, 17(1):37-41.
25. Presta L. Interleukin-10 Antibodies 2005, Schering Corporation, World Intellectional Property Organization.
26. Redpath S., Angulo A., Gascoigne N.R., Ghazal P. Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J. Immunol. 1999, 162(11):6701-6707.
27. Reiser M., Marousis C.G., Nelson D.R., Lauer G., Gonzalez-Peralta R.P., Davis G.L., Lau J.Y. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J. Hepatol. 1997, 26(3):471-478.
28. Slobedman B., Barry P.A., Spencer J.V., Avdic S., Abendroth A. Virus-encoded homologs of cellular interleukin-10 and their control of host immune function. J. Virol. 2009, 83(19):9618-9629.
29. Spencer J.V. The cytomegalovirus homolog of interleukin-10 requires phosphatidylinositol 3-kinase activity for inhibition of cytokine synthesis in monocytes. J. Virol. 2007, 81(4):2083-2086.
30. Spencer J.V., Lockridge K.M., Barry P.A., Lin G., Tsang M., Penfold M.E., Schall T.J. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J. Virol. 2002, 76(3):1285-1292.